Author/Authors :
Manoranjan, Branavan Michael G. DeGroote School of Medicine - McMaster University, Hamilton, Canada , Mahendram, Sujeivan McMaster Stem Cell and Cancer Research Institute - McMaster University, Hamilton, Canada , Almenawer, Saleh A. Departments of Surgery - Faculty of Health Sciences - McMaster University, Hamilton, Canada , Venugopal, Chitra McMaster Stem Cell and Cancer Research Institute - McMaster University, Hamilton, Canada , McFarlane, Nicole McMaster Stem Cell and Cancer Research Institute - McMaster University, Hamilton, Canada , Hallett, Robin McMaster Stem Cell and Cancer Research Institute - McMaster University, Hamilton, Canada , Vijayakumar, Thusyanth McMaster Stem Cell and Cancer Research Institute - McMaster University, Hamilton, Canada , Algird, Almunder McMaster Stem Cell and Cancer Research Institute - McMaster University, Hamilton, Canada , Murty, Naresh K. Departments of Surgery - Faculty of Health Sciences - McMaster University, Hamilton, Canada , Sommer, Doron D. Departments of Surgery - Faculty of Health Sciences - McMaster University, Hamilton, Canada , Provias, John P. Departments of pathology - Faculty of Health Sciences - McMaster University, Hamilton, Canada , Reddy, Kesava Departments of Surgery - Faculty of Health Sciences - McMaster University, Hamilton, Canada , Singh, Sheila K. Departments of Surgery - Faculty of Health Sciences - McMaster University, Hamilton, Canada
Abstract :
Classified as benign central nervous system (CNS) tumors, pituitary adenomas account for 10% of diagnosed intracranial neoplasms. Although surgery is often curative, patients with invasive macroadenomas continue to experience significant morbidity and are prone to tumor recurrence. Given the identification of human brain tumor-initiating cells (TICs) that initiate and maintain tumor growth while promoting disease progression and relapse in multiple CNS tumors, we investigated whether TICs also drive the growth of human pituitary adenomas. Using a nanoString-based 80-gene custom codeset specific for developmental pathways, we identified a differential stem cell gene expression profile within human pituitary adenomas. Prospective functional characterization of stem cell properties in patient-derived adenomas representing all hormonal subtypes yielded a subtype-dependent self-renewal profile, which was enriched within the CD15+ cell fraction. The tumor-initiating capacity of CD15high adenoma cells was assayed in comparison to CD15low adenomas using in vivo limiting dilutions, which maintained the rare frequency of TICs. Repeated analyses using sorted cell populations for CD15+ TICs compared to CD15- adenoma cells provided further evidence of xenograft tumor formation to support CD15+ cells as putative pituitary adenoma-initiating cells (PAICs). The clinical utility of our findings was established through in silico analyses and comparative gene expression profiling of primary and recurrent pituitary adenomas. CD15 was enriched in recurrent adenomas, which was validated using routine clinical immunohistochemistry in a limited number of samples. Our work reports the first prospective identification of human PAICs using CD15. Patients with CD15high adenomas may therefore benefit from more aggressive surgical interventions and chemo/radiotherapy.
